new_0222_0503|GMTX|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
new_0222_0503|GMTX|Long Name|1|1|Gemini Therapeutics Inc Total Current Assets (Quarterly) (USD)|Gemini Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Gemini Therapeutics Inc Inventories (Quarterly) (USD)|Gemini Therapeutics Inc Net PP&E (Quarterly) (USD)|Gemini Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Gemini Therapeutics Inc Total Liabilities (Quarterly) (USD)|Gemini Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Gemini Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Gemini Therapeutics Inc Total Deposits (Quarterly) (USD)|Gemini Therapeutics Inc Book Value (Quarterly) (USD)|Gemini Therapeutics Inc Retained Earnings (Quarterly) (USD)|Gemini Therapeutics Inc Treasury Stock (Quarterly) (USD)|Gemini Therapeutics Inc EV to Revenues|Gemini Therapeutics Inc EV to Earnings|Gemini Therapeutics Inc EV to Free Cash Flow|Gemini Therapeutics Inc EV to Assets (Quarterly)|Gemini Therapeutics Inc PS Ratio|Gemini Therapeutics Inc PE Ratio|Gemini Therapeutics Inc Price to Book Value|Gemini Therapeutics Inc PEG Ratio|Gemini Therapeutics Inc Debt to Equity Ratio|Gemini Therapeutics Inc Dividend Yield|Gemini Therapeutics Inc Shareholder Yield (TTM)|Gemini Therapeutics Inc Percent of Shares Outstanding Short|Gemini Therapeutics Inc Total Receivables (Quarterly) (USD)|Gemini Therapeutics Inc Total Payables (Quarterly) (USD)|Gemini Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Gemini Therapeutics Inc Return on Invested Capital|Gemini Therapeutics Inc Quality Ratio Score|Gemini Therapeutics Inc Momentum Score|Gemini Therapeutics Inc Beta (1Y)|Gemini Therapeutics Inc Sustainable Growth Rate (TTM)|Gemini Therapeutics Inc Institutional Investor Ownership Percentage|Gemini Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Gemini Therapeutics Inc Total Employees (Annual)|Gemini Therapeutics Inc EPS Diluted (Quarterly) (USD)|Gemini Therapeutics Inc Shares Outstanding|Gemini Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Gemini Therapeutics Inc Ordinary Shares Number (Quarterly)|Gemini Therapeutics Inc Payout Ratio|Gemini Therapeutics Inc Quick Ratio (Quarterly)|Gemini Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Gemini Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Gemini Therapeutics Inc Effective Tax Rate (TTM)|Gemini Therapeutics Inc Return on Equity|Gemini Therapeutics Inc Net Income (TTM) (USD)|Gemini Therapeutics Inc Revenue (TTM) (USD)|Gemini Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Gemini Therapeutics Inc Revenue (Quarterly) (USD)|Gemini Therapeutics Inc Gross Profit (Quarterly) (USD)|Gemini Therapeutics Inc SG&A Expense (Quarterly) (USD)|Gemini Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Gemini Therapeutics Inc Net Income (Quarterly) (USD)|Gemini Therapeutics Inc Net Interest Income (Quarterly) (USD)|Gemini Therapeutics Inc Price (USD)|Gemini Therapeutics Inc Total Return Price (USD)|Gemini Therapeutics Inc Enterprise Value (USD)|Gemini Therapeutics Inc 30-Day Average Daily Volume|Gemini Therapeutics Inc 1 Year Price Returns (Daily)
new_0222_0503|GMTX|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
new_0222_0503|GMTX||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily
new_0222_0503|GMTX||5|5|91.5|91.5|0|91.5|0|91.5|91.5|91.5|0|91.5|91.5|0|0|0|1.44090909091|0|0|0|1.44090909091|0|0|1.4375|0|15.347826087|0|91.5|91.5|0|0|0|0|0|30.6363636364|91.3333333333|0|91.3333333333|34.25|0|91.5|0|0|91.3333333333|0|0|0|91|0|0|0|0|91.3333333333|91.3333333333|91.3333333333|91.3333333333|1.4375|1.4375|1.44090909091|1.43612334802|1
new_0222_0503|GMTX||6|6|2|2|0|2|0|2|2|2|0|2|2|0|0|0|220|0|0|0|220|0|0|256|0|23|0|2|2|0|0|0|0|0|11|6|0|6|8|0|2|0|0|6|0|0|0|3|0|0|0|0|6|6|6|6|256|256|220|227|3
new_0222_0503|GMTX||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
new_0222_0503|GMTX|202003|202003|202003||||||||||||||||||||||||||||||||||45.302||-0.2151||||||-0.2152|||||||||1.414|-9.746|-9.746|-0.117|||||
new_0222_0503|GMTX|202006|202006|202006||||||||||||||||||||||||||||||||||45.302||-0.1495||||||-0.1495|||||||||1.138|-6.773|-6.773|-0.107|||||
new_0222_0503|GMTX|202009|202009|202009||||||||||||||||||||||||||||||||||45.302||-0.2208||||||-0.2206|||||||||1.222|-10.003|-10.003|-2.046|||||
new_0222_0503|GMTX|202012|202012|202012||||||||||||||||||||||||||||||||||45.302|3|0.2029||||||0.2029||||-17.3315|||||-0.5053|9.1905|9.1905|2.0505|||||
new_0222_0503|GMTX|202102|202012|202012||||||||||||||||||||||0||0.0619|||||||||4.2416||||45.302||||||||||||||||||15.2|15.2|||
new_0222_0503|GMTX|202103|202103|202103|188.605|184.986||0.229||18.221|13.776|4.445||171.161|-131.869||||-10.4684||||3.4043|||0||2.6835||3.562|0.004||||||71.4775|32.0272||-0.59|43.0021||43.0021|||-0.59||||-26.6335|||||4.704|-19.048|-19.048|-1.847|13.55|13.55|406.8215|300434.5667|
new_0222_0503|GMTX|202104|202103|202103|||||||||||||||-8.4102||||2.937|||0||2.6862|||||||||71.848||||||||||||||||||||||11.69|11.69|326.8375|320401|
new_0222_0503|GMTX|202105|202103|202103|||||||||||||||-9.1013||||3.0939|||0||2.7267|||||||||72.776||||43.0529||||||||||||||||||12.3|12.3|353.6937|187765.6667|
new_0222_0503|GMTX|202106|202106|202106|171.311|167.477||0.229||14.74|11.505|3.235||157.682|-148.316||||-2.6493||||1.7666|||0||4.905||1.492|0.004||||||76.4188|43.0419||-0.38|43.0551||43.0551|||-0.3797||||-36.3075|||||5.478|-16.447|-16.447|-0.116|6.47|6.47|118.9785|703835.9|
new_0222_0503|GMTX|202107|202106|202106|||||||||||||||-0.3484||||1.1113|||0||4.575|||||||||74.1357||||||||||||||||||||||4.07|4.07|15.6463|777692.6333|
new_0222_0503|GMTX|202108|202106|202106|||||||||||||||-1.1693||||1.3451|||0||4.3866|||||||||73.6469||||43.1095||||||||||||||||||4.92|4.92|52.5107|265568.3|
new_0222_0503|GMTX|202109|202109|202109|154.8|150.069||0.18||14.674|12.661|2.013||140.861|-166.867||||-0.5689||||1.2365|||0||4.105||0.939|0.004||||||84.6384|43.0918||-0.43|43.1127||43.1127|||-0.43||||-44.8555|||||4.995|-18.551|-18.551|-0.099|4.04|4.04|30.7533|276325.6|
new_0222_0503|GMTX|202110|202109|202109|||||||||||||||-0.3775||||1.163|||0||4.2026|||||||||84.696||||||||||||||||||||||3.8|3.8|20.4063|101908.1|
new_0222_0503|GMTX|202111|202109|202109|||||||||||||||0.452||||0.8447|||0||4.0621|||||||||84.7467||||43.1127||||||||||||||||||2.76|2.76|-24.4309|107254.5667|
new_0222_0503|GMTX|202112|202112|202112|||||||||||||||0.3323||||0.8907|||0||4.7199|||||||||83.6514||||||||||||||||||||||2.91|2.91|-17.964|2331780.5667|
new_0222_0503|GMTX|202201|202112|202112|||||||||||||||1.09||||0.5999|||0||4.1753|||||||||80.3919||||||||||||||||||||||1.96|1.96|-58.9211|346413.4667|
new_0222_0503|GMTX|202202|202112|202112|||||||||||||||1.3452||||0.5019|||0|||||||||||||||||||||||||||||||||1.64|1.64|-72.7172|200817.1|-87.1373